# US 2010/0143405 A1 · Immunotherapy of virus infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0143405 A1
- Document ID: US20100143405A1
- Status: Published application
- Kind: A1
- Application number: 11/661,098
- Filed: 2005-08-25
- Published: 2010-06-10
- Earliest claimed: 2004-08-26
- Inventors: David Charles Jackson; Lorena Elizabeth Brown; Lau Yuk Fai; Eric James Gowans
- Web page: https://patentgrep.com/patent/US20100143405A1

## CPC

- A61K 39/29: Hepatitis virus
- A61K 39/12: Viral antigens
- A61K 40/19: Dendritic cells
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/46: Viral antigens
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 31/20: for DNA viruses
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/543: {intranasal}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- A61K 2039/55572: {Lipopolysaccharides; Lipid A; Monophosphoryl lipid A}
- A61K 2239/31: characterized by the route of administration
- C12N 2770/24234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to a method of treating or preventing a virus infection in a subject. In particular, it relates to the use of autologous dendritic cells that have been matured and loaded ex vivo with hepatitis C virus (HCV) antigens, to initiate a cellular immune response in HCV-positive patients, after autologous transfusion.

## Claims

### Claim 1

A method of therapy for treating a viral infection in a subject, the method comprising:
(a) generating a concentrated ex vivo population of autologous dendritic cells;
(b) exposing the autologous dendritic cells to lipopetides comprising T helper and viral CTL epitopes and/or antibody epitopes; and;
(c) introducing the autologous dendritic cells into the subject, thus producing an enhanced immune response to the viral infection.

### Claim 2

A method of therapy for treating a viral infection in a subject, the method comprising:
(a) harvesting cells from a subject;
(b) generating a concentrated population of dendritic cells from the harvested cells;
(c) exposing the dendritic cells to lipopeptides comprising T helper and viral CTL epitopes and/or antibody epitopes; and
(d) re-introducing the dendritic cells into the subject.

### Claim 3 (depends on 1)

A method according to claim 1, wherein the lipopeptide has a lipid moiety attached via the terminal side chain epsilon-amino group of an internal lysine or lysine analog.

### Claim 4 (depends on 1)

A method according to claim 1 wherein the lipopeptide comprises a polypeptide conjugated to one or more lipid moieties wherein:
(i) said polypeptide comprises an amino acid sequence that comprises:
(a) the amino acid sequence of a T helper cell (Th) epitope and the amino acid sequence of a CTL epitope, wherein said amino acid sequences are different; and
(b) one or more internal lysine residues or internal lysine analog residues for covalent attachment of each of said lipid moieties via the epsilon-amino group or terminal side-chain group of said lysine or lysine analog; and
(ii) each of said one or more lipid moieties is covalently attached directly or indirectly to an epsilon-amino group of said one or more internal lysine residues or to a terminal side-chain group of said internal lysine analog residues.

### Claim 5 (depends on 1)

A method according to claim 1 wherein the lipopeptide is one in which the lipid moiety is S-[2,3-bis(palmitoyloxy)-propyl]-cysteine (Pam2Cys).

### Claim 6 (depends on 2)

A method according to claim 2 wherein the lipopeptide is one in which the CTL epitope is derived from the group consisting of Hepatitis C Virus (HCV), Hepatitis B Virus (HBV) and Human Immunodeficiency Virus (HIV).

### Claim 7 (depends on 6)

A method according to claim 6 wherein the lipopeptide is one in which the CTL epitope is derived from HCV.

### Claim 8 (depends on 7)

A method according to claim 7 wherein the HCV CTL epitope is selected from the group consisting of DLMGYIPLV (SEQ ID No:1), YLLPRRGPRL (SEQ ID No:2), FLLALLSCLTV (SEQ ID No:3), KLVALGINAV (SEQ ID No:4), CINGVCWTV (SEQ ID No:5), LLFNILGGWV (SEQ ID No: 6) or ILAGYGAGV (SEQ ID No:7).

### Claim 9 (depends on 1)

A method according to claim 1 wherein the lipopeptide is one in which the Th epitope is KLIPNASLIENCTKAEL (SEQ ID No:8).

### Claim 10

A population of lipopeptide pulsed dendritic cells (DCs) produced according to a method comprising:
(a) generating a concentrated ex vivo population of autologous dendritic cells;
(b) exposing the autologous dendritic cells to lipopeptides comprising T helper and viral CTL epitopes and/or antibody epitopes; and
(c) introducing the autologous dentridic cells into the subject.

### Claim 11

A population of lipopeptide pulsed dendritic cells (DCs) produced according to a method comprising:
(a) harvesting cells from a subject;
(b) generating a concentrated population of dendritic cells from the harvested cells.
(c) exposing the dendritic cells to lipopeptides comprising T helper and viral CTL epitopes and/or antibody epitopes; and
(d) re-introducing the dendritic cells into the subject.

### Claim 12 (depends on 10)

A population according to claim 10, wherein the lipopeptide is one in which the lipid moiety is S-[2,3-bis(palmitoyloxy)-propyl]-cysteine (Pam2Cys).

### Claim 13 (depends on 10)

A population according to claim 10, wherein the lipopeptide is one in which the CTL epitope is derived from the group consisting of Hepatitis C Virus (HCV), Hepatitis B Virus (HBV) and Human Immunodeficiency Virus (HIV).

### Claim 14 (depends on 13)

A population according to claim 13, wherein the lipopeptide is one in which the CTL epitope is derived from HCV.

### Claim 15 (depends on 14)

A population according to claim 14 wherein the HCV CTL epitope is selected from the group consisting of DLMGYIPLV (SEQ ID No:1), YLLPRRGPRL (SEQ ID No:2), FLLALLSCLTV (SEQ ID No:3), KLVALGINAV (SEQ ID No:4), CINGVCWTV (SEQ ID No:5), LLFNILGGWV (SEQ ID No: 6) or ILAGYGAGV (SEQ ID No:7).

### Claim 16 (depends on 10)

A population according to claim 10 wherein the lipopeptide is one in which the Th epitope is KLIPNASLIENCTKAEL (SEQ ID No:8).

### Claim 17 (depends on 10)

Use of a population of lipopeptide pulsed dendritic cells (DCs) for treating a virus-infected subject, comprising re-introducing into the subject, dendritic cells (DCs) prepared according to claim 10.

### Claim 18 (depends on 17)

Use according to claim 17 wherein the lipopeptide pulsed dendritic cells are reintroduced into the subject in the form of a vaccine administered to the subject together with a pharmaceutically acceptable excipient or diluent.

### Claim 19 (depends on 17)

Use according to claim 17 wherein the subject has a chronic HCV infection.

### Claim 20

A method for inducing cell mediated immunity in a subject, the method comprising treating a subject according to the method of the first aspect of the invention for a time and under conditions sufficient to activate a CTL of the subject.

### Claim 21

A method for the prophylactic treatment of an uninfected subject, the method comprising:
(a) generating a concentrated ex vivo population of autologous dendritic cells;
(b) exposing the autologous dendritic cells to lipopeptides comprising T helper and viral CTL epitopes and/or antibody epitopes; and
(c) introducing the autologous dendritic cells into the subject, thus producing an enhanced immune response to the viral infection.

### Claim 22

A method for the prophylactic treatment of an uninfected subject, the method comprising:
(a) harvesting cells from a subject;
(b) generating a concentrated population of dendritic cells from the harvested cells;
(c) exposing the dendritic cells to lipopeptides comprising T helper and viral CTL epitopes and/or antibody epitopes; and
(d) re-introducing the dendritic cells into the subject.
